DOI QR코드

DOI QR Code

miR-340 Reverses Cisplatin Resistance of Hepatocellular Carcinoma Cell Lines by Targeting Nrf2-dependent Antioxidant Pathway

  • Shi, Liang (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) ;
  • Chen, Zhan-Guo (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Wu, Li-li (Department of Clinical Laboratory, The Dingli Clinical College of Wenzhou Medical University) ;
  • Zheng, Jian-Jian (Wenzhou Key Laboratory of Surgery, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Yang, Jian-Rong (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Chen, Xiao-Fei (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Chen, Zeng-Qiang (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Liu, Cun-Li (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Chi, Sheng-Ying (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Zheng, Jia-Ying (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Huang, Hai-Xia (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Lin, Xiang-Yang (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Zheng, Fang (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University)
  • Published : 2015.01.06

Abstract

Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC); however, the development of chemoresistance in liver cancer cells usually results in a relapse and worsening of prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles in chemotherapy resistance. Currently, extensive research has shown that there is another potential mechanism of gene expression control, which is mediated through the function of short noncoding RNAs, especially for microRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, by taking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, it has been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays of Nrf2-3'-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR-340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/CDDP cells to cisplatin. Interestingly, transfection with miR-340 mimics combined with miR-340 inhibitors reactivated the Nrf2 related pathway and restored the resistance of HepG2/CDDP cells to CDDP. Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.

Keywords

Hepatocellular carcinoma cell lines;miR-340;Nrf2;cisplatin;chemoresistance

Acknowledgement

Supported by : National Basic Research Program of China

References

  1. Bao LJ, Jaramillo MC, Zhang ZB, et al (2014). Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol, 7, 1502-13.
  2. Niture SK, Kaspar JW, Shen J, et al (2010). Nrf2 signaling and cell survival. Toxicol Appl Pharmacol, 244, 37-42. https://doi.org/10.1016/j.taap.2009.06.009
  3. Sangokoya C, Telen MJ, Chi JT (2010). microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood, 116, 4338-48. https://doi.org/10.1182/blood-2009-04-214817
  4. He X, Ma Q (2010). Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol
  5. Hsieh MY, Lin ZY, Chen SH, et al (2011). Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci, 27, 431-6. https://doi.org/10.1016/j.kjms.2011.06.001
  6. Lavi O, Skinner J, Gottesman MM (2014). Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol, 8, 88. https://doi.org/10.1186/s12918-014-0088-0
  7. Gaur A, Jewell DA, Liang Y, et al (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res, 67, 2456-68. https://doi.org/10.1158/0008-5472.CAN-06-2698
  8. Shi XB, Tepper CG, deVere White RW (2008). Cancerous miRNAs and their regulation. Cell Cycle, 7, 1529-38. https://doi.org/10.4161/cc.7.11.5977
  9. Giovannetti E, Erozenci A, Smit J, et al (2012). Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol, 81, 103-22. https://doi.org/10.1016/j.critrevonc.2011.03.010
  10. Hu Q, Gong JP, Li J, et al (2014). Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev, 15, 5137-42. https://doi.org/10.7314/APJCP.2014.15.13.5137
  11. Wang HJ, Guo YQ, Tan G, et al (2013). miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem, 114, 2248-57. https://doi.org/10.1002/jcb.24574
  12. Yamaguchi T, Nakajima N, Nakamura I, et al (2013). Preclinical anticancer effects and toxicologic assessment of hepatic artery infusion of fine-powder cisplatin with lipiodol in vivo. Drug Discov Ther, 7, 201-8.
  13. Yang JX, Luo Y, Qiu HM, et al (2009). Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Saudi Med J, 30, 35-40.
  14. Chen Y, Fu LL, Wen X, et al (2014). Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis, 19, 1177-89. https://doi.org/10.1007/s10495-014-0999-7
  15. Robertson NM, Yigit MV (2014). The role of microRNA in resistance to breast cancer therapy. Wiley Interdiscip Rev RNA.

Cited by

  1. miRNA Influences in NRF2 Pathway Interactions within Cancer Models vol.2015, pp.2090-021X, 2015, https://doi.org/10.1155/2015/143636
  2. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells vol.35, pp.1, 2016, https://doi.org/10.1186/s13046-016-0296-0
  3. MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2 vol.36, pp.2, 2016, https://doi.org/10.3892/or.2016.4876
  4. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma vol.50, pp.5, 2017, https://doi.org/10.1590/1414-431x20176359
  5. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance vol.8, pp.3, 2017, https://doi.org/10.3390/genes8030095
  6. microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5 vol.35, pp.1, 2016, https://doi.org/10.1089/dna.2015.3021
  7. SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis vol.37, pp.9, 2018, https://doi.org/10.1038/s41388-017-0029-7
  8. Non-coding RNA in drug resistance of hepatocellular carcinoma vol.38, pp.5, 2018, https://doi.org/10.1042/BSR20180915
  9. The Network of Non-coding RNAs in Cancer Drug Resistance vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00327
  10. NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis pp.1873-961X, 2018, https://doi.org/10.1007/s12079-018-0479-x
  11. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing vol.25, pp.9, 2018, https://doi.org/10.1245/s10434-018-6626-z
  12. miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1 vol.29, pp.5, 2018, https://doi.org/10.1097/CAD.0000000000000614
  13. confers adverse clinical outcome in patients with acute myeloid leukemia vol.234, pp.4, 2018, https://doi.org/10.1002/jcp.27178
  14. MicroRNA replacement therapy in cancer pp.00219541, 2019, https://doi.org/10.1002/jcp.28058
  15. MicroRNA-mediated redox regulation modulates therapy resistance in cancer cells: clinical perspectives pp.2211-3436, 2019, https://doi.org/10.1007/s13402-018-00421-z
  16. The role and mechanisms of action of microRNAs in cancer drug resistance vol.11, pp.1, 2019, https://doi.org/10.1186/s13148-018-0587-8
  17. The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches vol.9, pp.1663-9812, 2019, https://doi.org/10.3389/fphar.2018.01428